Weight-care map / product and purpose
A shared ingredient can have different uses
An ingredient is the part that does the work. Ask for its name and the product name.
FDA, the Food and Drug Administration, approves specific products for specific uses.
Medicine approvals and supply as of September 2026.
Semaglutide versus tirzepatide: ask which product is meant
Semaglutide (Ozempic, Wegovy)
Wegovy is approved for weight loss and for keeping the loss long term.
Ozempic products have approved uses linked to type 2 diabetes, a condition with high blood sugar.
Both brand names cover pills and shots in the September 2026 records.
Ask whether it is a pill or shot and what it is meant to treat.
Tirzepatide (Mounjaro, Zepbound)
Mounjaro has approved uses linked to type 2 diabetes.
Weight care and certain kinds of sleep apnea are approved uses for Zepbound.
Sleep apnea means breathing pauses in sleep. Ask why this product fits the plan.
A shared ingredient does not make every use the same.
Approval names a product and its uses. It does not promise a result for each person.
Read the records behind this ↓Is making it to order the same as a generic?
In September 2026, neither semaglutide nor tirzepatide had a generic with FDA approval that could be sold.
Calling a medicine prepared to order a generic of an approved drug is misleading, FDA says.
A copy of a brand-name drug follows the generic route when it receives approval. Compounding means making the drug to order. These are separate paths.
Are all weight-loss drugs in the same position?
Liraglutide (Victoza, Saxenda) has approved generic versions for weight care in the September 2026 check.
An approval record still does not prove that the drug is on shelves.
Ask which product is on hand for the proposed use. Keep the answer with its name.
What about a drug still being studied?
United States approval was still absent for retatrutide in September 2026.
FDA also says federal law does not allow it to be used in compounding.
Ask for the exact status behind a headline about a new treatment. A study headline leaves the access question unanswered.
Notes for this page
These notes use the rules and care records checked in September 2026.
A · Semaglutide injection for diabetes-related uses
FDA: Ozempic label ↗B · Semaglutide pills, shots and approved uses
FDA: Wegovy label ↗C · Tirzepatide’s Mounjaro uses
FDA: Mounjaro label ↗D · Tirzepatide and sleep-apnea care
FDA: Zepbound sleep-apnea approval ↗E · The status of unapproved preparations
FDA: unapproved weight-loss medicines ↗F · Approved liraglutide generic labels
FDA: liraglutide label records ↗